Overview

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.
Phase:
Phase 1
Details
Lead Sponsor:
Tobira Therapeutics, Inc.
Treatments:
Cenicriviroc
Pioglitazone
TAK-652